| Name | BMS-986020 |
|---|---|
| Synonyms |
1-{4'-[3-Methyl-4-({[(1R)-1-phenylethoxy]carbonyl}amino)-1,2-oxazol-5-yl]-4-biphenylyl}cyclopropanecarboxylic acid
Cyclopropanecarboxylic acid, 1-[4'-[3-methyl-4-[[[(1R)-1-phenylethoxy]carbonyl]amino]-5-isoxazolyl][1,1'-biphenyl]-4-yl]- |
| Description | BMS-986020 is an LPA1 antagonist.target: LPA1BMS-986020 is in Phase 2 clinical development for treating idiopathic pulmonary fibrosis. BMS-986020 selectively inhibits the LPA receptor, which is involved in binding of the signaling molecule lysophosphatidic acid, which in turn is involved in a host of diverse biological functions, such as cell proliferation, platelet aggregation, smooth muscle contraction and others. |
|---|---|
| Related Catalog | |
| References |
[1]. Kihara Y et al. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015 May 1;333(2):171-7. |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 664.8±55.0 °C at 760 mmHg |
| Molecular Formula | C29H26N2O5 |
| Molecular Weight | 482.527 |
| Flash Point | 355.9±31.5 °C |
| Exact Mass | 482.184174 |
| LogP | 4.99 |
| Vapour Pressure | 0.0±2.1 mmHg at 25°C |
| Index of Refraction | 1.647 |
| Storage condition | 2-8℃ |